KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Cash from Financing Activities (2016 - 2025)

Abbott Laboratories' Cash from Financing Activities history spans 17 years, with the latest figure at -$1.4 billion for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 24.93% year-over-year to -$1.4 billion; the TTM value through Dec 2025 reached -$6.3 billion, down 16.75%, while the annual FY2025 figure was -$6.3 billion, 16.75% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was -$1.4 billion at Abbott Laboratories, up from -$1.8 billion in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at -$791.0 million in Q2 2024 and bottomed at -$3.8 billion in Q1 2022.
  • The 5-year median for Cash from Financing Activities is -$1.4 billion (2022), against an average of -$1.6 billion.
  • The largest annual shift saw Cash from Financing Activities crashed 295.35% in 2022 before it skyrocketed 63.12% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at -$1.9 billion in 2021, then grew by 22.75% to -$1.5 billion in 2022, then crashed by 40.84% to -$2.1 billion in 2023, then increased by 9.31% to -$1.9 billion in 2024, then grew by 24.93% to -$1.4 billion in 2025.
  • Per Business Quant, the three most recent readings for ABT's Cash from Financing Activities are -$1.4 billion (Q4 2025), -$1.8 billion (Q3 2025), and -$1.1 billion (Q2 2025).